T-3262の変異原性試験

DOI

書誌事項

タイトル別名
  • MUTAGENICITY STUDIES ON T-3262
  • CYTOGENETIC STUDIES <I>IN VITRO</I> AND <I>IN VIVO</I>
  • 培養細胞及びマウスを用いた細胞遺伝学的試験

抄録

We investigated the mutagenicity of T-3262, a new antibacterial drug, both in vivo and in vivo systems, with the following results.<BR>1) Sister chromatid exchange (SCE) test and chromosomal aberration test (with or without metabolic activation) were carried out using cultured Chinese hamster cells (V 79 cells). No statistically significant differences in the frequency of SCEs and chromosomal aberrations were observed between T-3262-treated groups and the control.<BR>2) Chromosomal aberration and micronucleus tests were carried out in the bone marrow of mice given a single or five consecutive oral administrations of T-3262. No statistically significant differences in the frequency of chromosomal aberrations and micronuclei were found between T-3262-administered and the control groups.<BR>These results suggest that T-3262 has neither primary DNA damaging nor clastogenic activity.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ